Celltrion Sees U.S. Tariff Risk Resolved as Biosimilars Gain Exemption, Boosting Demand Outlook

The U.S. government has exempted biosimilars from new pharmaceutical tariffs for one year, removing a major uncertainty for Celltrion's core U.S. business.

This policy, combined with the FDA's push to streamline biosimilar approvals, creates a favorable environment for increased market adoption.

Celltrion's strategic investments in its U.S. manufacturing facility in New Jersey position it to meet rising local demand and align with onshoring trends.

셀트리온

Celltrion recently announced that the impact of U.S. pharmaceutical tariffs has been resolved, creating a positive outlook for its U.S. business.

This optimism stems directly from a key U.S. policy decision. The White House, using Section 232, imposed tariffs of up to 100% on patented drugs and their ingredients to encourage domestic production. However, it explicitly exempted biosimilars and generics for one year, subject to reassessment. This was a significant relief for Celltrion, as biosimilars are the backbone of its U.S. sales.

Several factors created this favorable outcome. First, the policy's structure itself is the primary cause. The proclamation on April 2, 2026, drew a clear line: high tariffs for patented drugs, but a temporary safe harbor for biosimilars. This instantly removed the most immediate threat to Celltrion's revenue stream.

Second, the broader industry environment is supportive. The U.S. Food and Drug Administration (FDA) has been working to simplify the approval process for biosimilars. By making it easier for these lower-cost alternatives to enter the market, the FDA is boosting the demand side of the equation. The tariff exemption removes a major cost barrier on the supply side, creating a powerful combination that could accelerate biosimilar adoption in the U.S.

Third, Celltrion's own strategic foresight played a crucial role. Well before the tariff announcement, the company had been investing heavily in its U.S. manufacturing capabilities. It acquired and began expanding a facility in Branchburg, New Jersey. This move to 'onshore' production not only mitigates future policy risks but also positions Celltrion to directly meet the rising local demand that these favorable conditions are expected to create.

In short, the combination of a specific policy exemption, a supportive regulatory trend, and proactive corporate strategy has transformed a potential crisis into a clear opportunity for Celltrion.

Glossary
Biosimilar: A biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.
Section 232: A provision of U.S. trade law that allows the president to impose tariffs on imports if they are determined to threaten national security.